ArticleOncotarget2017
The role of EGFR double minutes in modulating the response of malignant gliomas to radiotherapy.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 32 citations in OpenAlex.
- The potential clinical implications of extrachromosomal circular DNA as a biomarker.Genes & diseases · 2026Review
- Targeting extrachromosomal DNA in human cancers.Nature reviews. Drug discovery · 2026Review
- Extrachromosomal circular DNA: a potential clinical therapeutic target in malignant tumors.Cellular & molecular biology letters · 2026Review
- Profiling Extrachromosomal Circular DNA (ecDNA) in CancerAnti-cancer agents in medicinal chemistry · 2026Review
- Resolving spatial subclonal genomic heterogeneity of loss of heterozygosity and extrachromosomal DNA in gliomas.Nature communications · 2025Article
- Intercellular extrachromosomal DNA copy-number heterogeneity drives neuroblastoma cell state diversity.Cell reports · 2024Article
- Suberanilohydroxamic acid (SAHA), a HDAC inhibitor, suppresses the effect of Treg cells by targeting the c-Myc/CCL1 pathway in glioma stem cells and improves PD-L1 blockade therapy.Journal of neuro-oncology · 2024Article
- Review
- PLCG2 can exist in eccDNA and contribute to the metastasis of non-small cell lung cancer by regulating mitochondrial respiration.Cell death & disease · 2023Article
- Extrachromosomal circular DNA: biogenesis, structure, functions and diseases.Signal transduction and targeted therapy · 2022Review
- Revisiting characteristics of oncogenic extrachromosomal DNA as mobile enhancers on neuroblastoma and glioma cancers.Cancer cell international · 2022Review
- Pioneering insights of extrachromosomal DNA (ecDNA) generation, action and its implications for cancer therapy.International journal of biological sciences · 2022Review
- Extrachromosomal circular DNA in cancer drug resistance and its potential clinical implications.Frontiers in oncology · 2022Review
- Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug.Cell reports · 2021Article
- Small extrachromosomal circular DNA (eccDNA): major functions in evolution and cancer.Molecular cancer · 2021Review
- Extrachromosomal circular DNA: a new potential role in cancer progression.Journal of translational medicine · 2021Review
- Novel insights into extrachromosomal DNA: redefining the onco-drivers of tumor progression.Journal of experimental & clinical cancer research : CR · 2020Review
- Current understanding of extrachromosomal circular DNA in cancer pathogenesis and therapeutic resistance.Journal of hematology & oncology · 2020Review
- Review
- Dual antivascular function of human fibulin-3 variant, a potential new drug discovery strategy for glioblastoma.Cancer science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.